<DOC>
	<DOC>NCT02209584</DOC>
	<brief_summary>This registry is intended to measure the impact of Prolaris® testing on therapeutic decisions when added to standard clinical-pathological parameters in men with newly diagnosed prostate cancer.</brief_summary>
	<brief_title>Open Registry Measuring Impact of Genomic Testing on Treatment Decision After Biopsy in Newly Diagnosed Prostate Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Newly diagnosed (≤6 months), untreated patients with histologically proven adenocarcinoma of the prostate that have the following characteristics. Clinically localized (no evidence on clinical or imaging studies of advanced disease. No hormonal therapy including LHRH agonist or antagonist, antiandrogen, 5alpha reductase inhibitor, estrogens or exogenous androgens, when applicable. Sufficient amount of tissue remains from biopsy to perform genomic testing. Patients with known history of hypogonadism will be excluded from the registry</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>